Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry

(2012) Jeffrey D Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy

(2012) Maria A. Lopez-Olivo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

(2012) Yvonne M. R. de Punder et al.   RHEUMATOLOGY

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

(2012) M. E. Weinblatt et al.   RHEUMATOLOGY

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study

(2011) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy

(2011) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Golimumab Pharmacokinetics After Repeated Subcutaneous and Intravenous Administrations in Patients with Rheumatoid Arthritis and the Effect of Concomitant Methotrexate: An Open-Label, Randomized Study

(2011) Yanli Zhuang et al.   CLINICAL THERAPEUTICS

Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab

(2011) PETER C. TAYLOR et al.   JOURNAL OF RHEUMATOLOGY

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

(2010) Joel Kremer et al.   ARTHRITIS AND RHEUMATISM

Golimumab for Rheumatoid Arthritis: A Systematic Review

(2010) J. A. SINGH et al.   JOURNAL OF RHEUMATOLOGY

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008

(2010) K. L. Hyrich et al.   RHEUMATOLOGY

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

(2009) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Subcutaneous Bioavailability of Golimumab at 3 Different Injection Sites in Healthy Subjects

(2009) Zhenhua Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

(2009) Josef S Smolen et al.   LANCET

Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

(2008) E C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES